Upgrade to Outperform: Gilead Sciences' Stock on the Rise
Monday, 8 July 2024, 13:07
Upgrade to Outperform: Gilead Sciences' Stock Soars
Raymond James has upgraded Gilead Sciences stock to Outperform in light of...
Key Points:
- Positive Data: The upgrade follows encouraging data from the PURPOSE-1 study.
- Approval Prospects: Seladelpar's expected approval adds to the optimistic outlook.
Conclusion: Investors can expect a bright future for Gilead Sciences as it receives this positive rating.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.